VIB4920
VIB4920 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
1
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
VIBRANT: VIB4920 for Active Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
Clinical Trials (6)
VIBRANT: VIB4920 for Active Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6